ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Takeda halts development of COVID-19 plasma therapy

Japanese drugmaker had counted on technology boost from Shire acquisition

A nurse attends to a patient suffering from COVID-19 at a hospital in Spain.    © Reuters

TOKYO -- Takeda Pharmaceutical has suspended the development of a plasma therapy for COVID-19 after it failed to show effectiveness in clinical trials, according to a Tuesday disclosure to investors.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more